Welcome to: Rimonabant Information Source (rimonabant a stimulant)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Loss is necessary for good health and in the process, people of different options. Acomplia rimonabant is the latest anti-obesity drug for the treatment of overweight people suffering from type 2 diabetes, low HDL cholesterol or high triglycerides. However, it is better to buy Acomplia rimonabant only after proper medical consultation. Obese people suffering from heart disease Acomplia rimonabant can also buy and maintain weight loss. Side effects of Acomplia rimonabant The most common side effects seen in people who Acomplia slimming pill include nausea, dizziness and anxiety. Several clinical studies show positive results in favor of Acomplia, apart from some mild side effects and treatable.

Rimonabant Pricelist

Please wait while we load the price list
Diet programmes and exercise do help in reducing weight buy it works slowly. On the other hand, prescription drugs like Acomplia, Xenical are faster ways to obesity treatment. These are manufactured by renowned pharmaceutical companies and clinically approved for use. Acomplia (Rimonabant) for Obesity treatment Acomplia is a prescription drug for obesity treatment. A French pharmaceutical firm, Sanoti-Aventis manufactures Acomplia slimming pills, which have been approved for sale in the UK and many European countries. Acomplia contains Rimonabant as the active ingredient which works basically by reducing craving and urge to eat and produces a feeling of fullness. It basically acts as a cannabinoid type I (CB1) receptor and works in the brain to produce feelings of fullness even by eating less food.

All patients were at least 18 years old, had a history of type 2 diabetes diagnosed 2 months to 3 years prior to the study, and had no previous insulin therapy, other than insulin for gestational diabetes or for short-term hospitalization. None had taken oral antidiabetic drugs beyond 4 months, and such drugs were discontinued at least 6 months prior to the study. All had a stable weight, and Hb[A.sub. 1c] levels of at least 7% but no greater than 10%. The patients were treated at any of 56 centers in the United States, Argentina, Chile, Germany, Hungary, the Netherlands, and Poland. The study's primary end point was reduction in Hb[A.sub. 1c] level. At baseline, both study arms had a mean Hb[A.sub.